IP Library › Granted Patent US 8,569,450
Granted Patent B2
US 8,569,450 · App. 13/039,722 · Granted Oct 29, 2013

CD3 epsilon immunogens and antibodies

Inventors: Kenneth A. Pass (Glenmont, NY); Barbara Lindau-Shepard (Albany, NY); David K. Janik (Deer Park, NY)
Assignee: Health Research Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,569,450
App. No.
13/039,722
Granted
Oct 29, 2013
Kind
B2
Abstract

The present invention relates to novel CD3 epsilon peptides, antibodies against the novel CD3 epsilon peptides. The invention also relates to methods of identifying an immunodeficiency (such as severe combined immunodeficiency (SCID) or a T cell immunodeficiency) in a patient, which may involve antibodies against CD3 epsilon peptides.

Claims (2)

1. An isolated CD3 epsilon peptide consisting of 12 residues wherein residues 8-12 of the peptide are residues 8-12 of SEQ ID NO: 1 .

2. An isolated CD3 epsilon peptide consisting of SEQ ID NO: 1.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 23, 2012
From: HEALTH RESEARCH, INC./NYSDOH WADSWORTH CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029177/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2011
From: PASS, KENNETH A.; LINDAU-SHEPARD, BARBARA; JANIK, DAVID K.
To: HEALTH RESEARCH INC.
Reel/Frame 026301/0296 →
Continuity (4)
Provisional Application 61310199 · Mar 3, 2010
Provisional Application 61377833 · Aug 27, 2010
Provisional Application 61434745 · Jan 20, 2011
Related Publication 20110217790A1 · Sep 8, 2011